Please assess the completion status of the following clinical trial:

Trial Title: Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To qualify for this study, participants will need to have:~1. At least 18 years of age~2. Documented HIV-1 infection~3. CD4+ count \<350 cells/mm3 at the time of enrollment or CD4+ count increase of \<100 cells/mm3 within the past 2 years~4. Plasma viral load \<400 copies/ml at all testing time points within the preceding 2 years AND \<50 copies/ml by RT-PCR or \<75 copies/ml by bDNA at the 2 testing time points immediately preceding enrollment into the study~Exclusion Criteria:~To qualify for this study, patients must not meet any of the following exclusion criteria:~1. Pregnancy or breast-feeding~2. Prior use of raltegravir at any time in the past~3. Use of any investigational, immunomodulatory, immunosuppressive agents within 90 days prior or during this study~4. Alcohol or substance abuse that in the opinion of the investigator might interfere with patient compliance or safety~5. Any condition or pre-study laboratory abnormality that in the opinion of the investigator might interfere with patient compliance or safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Raltegravir and then Observation (Type: EXPERIMENTAL): The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
- Observation and then Raltegravir (Type: ACTIVE_COMPARATOR): The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).